Payment overview · 2025
General Payments
$176.21
10 reported records · 7 companies
Healthcare provider profile · identity verified
Nolan Jackson Beavers, M.D,
Allopathic & Osteopathic Physicians|Family Medicine · BELLEVILLE, KS · NPI 1104921782
Verified facts
What the public records show
CMS Open Payments records show Nolan Jackson Beavers, M.D, received $176.21 in general payments during 2025 across 10 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $44.26 | 25.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.10 | 24.5% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $24.32 | 13.8% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.36 | 9.8% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.21 | 9.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.04 | 8.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.92 | 8.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $176.21 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $44.26 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $24.32 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.21 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 419 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 306 | 67 |
| Furosemide | Furosemide | 293 | 60 |
| Lisinopril | Lisinopril | 234 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 226 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 201 | 47 |
| Eliquis | Apixaban | 197 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 160 | 46 |
| Potassium Chloride | Potassium Chloride | 160 | 41 |
| Losartan Potassium | Losartan Potassium | 155 | 32 |
| Warfarin Sodium | Warfarin Sodium | 141 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 31 |
| Simvastatin | Simvastatin | 131 | 25 |
| Gabapentin | Gabapentin | 125 | 28 |
| Carvedilol | Carvedilol | 120 | 25 |
| Omeprazole | Omeprazole | 115 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 20 |
| Atenolol | Atenolol | 111 | 28 |
| Montelukast Sodium | Montelukast Sodium | 104 | 23 |
| Celecoxib | Celecoxib | 101 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 33 |
| Jardiance | Empagliflozin | 99 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 19 |
| Xarelto | Rivaroxaban | 96 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 23 |
| Donepezil Hcl | Donepezil Hcl | 89 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 23 |
| Prednisone | Prednisone | 84 | 42 |
| Ozempic | Semaglutide | 83 | 12 |
| Metformin Hcl | Metformin Hcl | 81 | 18 |
| Metformin Hcl Er | Metformin Hcl | 80 | 16 |
| Nifedipine Er | Nifedipine | 80 | 17 |
| Sertraline Hcl | Sertraline Hcl | 77 | 14 |
| Tramadol Hcl | Tramadol Hcl | 77 | 14 |
| Pregabalin | Pregabalin | 75 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 71 | 15 |
| Trazodone Hcl | Trazodone Hcl | 71 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 12 |
| Lorazepam | Lorazepam | 68 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 11 |
| Allopurinol | Allopurinol | 65 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 18 |
| Glimepiride | Glimepiride | 61 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 57 | suppressed |
| Cephalexin | Cephalexin | 57 | 43 |
| Tresiba Flextouch U-200 | Insulin Degludec | 57 | suppressed |
| Alprazolam | Alprazolam | 56 | 13 |
| Azithromycin | Azithromycin | 56 | 51 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 15 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 53 | 53 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 53 | 39 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Glipizide Er | Glipizide | 50 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | suppressed |
| Fentanyl | Fentanyl | 46 | 11 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 44 | suppressed |
| Baclofen | Baclofen | 43 | suppressed |
| Finasteride | Finasteride | 43 | 12 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Chlorthalidone | Chlorthalidone | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 41 | suppressed |
| Invokana | Canagliflozin | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 30 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 38 | 38 |
| Verapamil Er | Verapamil Hcl | 37 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 22 |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Dulera | Mometasone/Formoterol | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 16 |
| Digoxin | Digoxin | 20 | suppressed |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 20 | 20 |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Enbrel | Etanercept | 12 | suppressed |
| Ethosuximide | Ethosuximide | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $176.21 · 10 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, NUZYRA, QULIPTA, REXULTI, SMARTVEST, UBRELVY, VRAYLAR, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error